Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine
The NYAS’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms brings together thought leaders to advance this growing frontier of patient care
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Executive Chairman William Doyle will present at the New York Academy of Sciences’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms on Friday, Sept. 23, 2016. Mr. Doyle’s presentation “Tumor Treating Fields – A Novel Cancer Therapy Utilizing Alternating Electric Fields” will focus on Novocure’s innovative treatment for solid tumors.
The symposium brings together thought leaders of bioelectronic medicine, which NYAS describes as the epicenter of where healthcare, technology and science converge and a science that may change the future of therapies for a wide variety of diseases.
“I am honored to share the science of Tumor Treating Fields (TTFields) at this prestigious event,” Mr. Doyle said. “Treatment with TTFields significantly prolongs survival of patients with newly diagnosed glioblastoma without the cancer therapy side effects that commonly compromise quality of life. We are committed to bringing TTFields therapy to GBM patients and to advancing our clinical pipeline in other solid tumor cancers.”
Novocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media and Investor Contact:
Ashley Cordova, 212-767-7558